Modest setback for Sun Pharma, 18% fall in SPARC shares...
Sun Pharma announced results for its clinical trial program SCD-044 which failed to meet the end point in a Phase-2 trial and is discontinuing the program. While the stock of...
Sun Pharma announced results for its clinical trial program SCD-044 which failed to meet the end point in a Phase-2 trial and is discontinuing the program. While the stock of...
